Facial lipodystrophy after immunotherapy with Nivolumab

J Dtsch Dermatol Ges. 2021 Oct;19(10):1513-1515. doi: 10.1111/ddg.14588. Epub 2021 Sep 27.

Authors

Konstantin Drexler¹, Veronika Zenderowski¹, Mark Berneburg¹, Sebastian Haferkamp¹

Affiliation

¹ Klinik und Poliklinik für Dermatologie, Universitätsklinikum Regensburg.

PMID: 34569153
DOI: 10.1111/ddg.14588

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents, Immunological* / adverse effects
Humans
Immunologic Factors
Immunotherapy / adverse effects
Lipodystrophy*
Nivolumab / adverse effects

Substances

Antineoplastic Agents, Immunological
Immunologic Factors
Nivolumab